This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Joan Stephenson, PhD

JAMA. 2001;285:3077-3078.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

San Francisco—Two proteins linked to tumor invasion and metastasis can help identify women with breast cancer whose risk of recurrence is low enough that they may want to consider forgoing chemotherapy, according to new research presented here at the American Society of Clinical Oncology (ASCO) annual meeting.

The researchers say that these findings, along with new data from a prospective clinical trial, are convincing enough to recommend routine testing for the two proteins to help determine treatment strategy, particularly for breast cancer patients whose axillary lymph nodes show no sign of cancer cells.

The two proteins, urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1), are considered to play an important role in tumor invasion and metastasis through degradation of the extracellular matrix that binds normal cells together in tissues. Studies have found that uPA and PAI-1 are found in significantly greater amounts in malignancies . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?